Ablation

Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV

Retrieved on: 
Monday, November 1, 2021
Safety, MPV, Infection, Political movement, Pemphigus vulgaris, Disease, Annual report, Autoantibody, Ablation, CAR, Security (finance), U.S. Securities and Exchange Commission, Patient, DSG1, Private Securities Litigation Reform Act, FDA, Risk, Time, MuSK protein, Immunity, Protein, Company, Pemphigus, DSG3, Clinical trial, COVID-19, Skin, Desmoglein-1, Form 10-K, Cell, Health, Observation, Infrared spectroscopy correlation table, GLOBE, Vaccine, Pharmaceutical industry

PHILADELPHIA, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced 28-day clinical data from the third dose cohort using 500 million DSG3-CAART cells in the DesCAARTes™ Phase 1 clinical trial for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV).

Key Points: 
  • The rapid pace of the clinical trial has been possible due to the enthusiasm and engagement of patients, investigators and patient advocacy groups.
  • Dosing of patients in the fourth cohort at a treatment dose of 2.5 billion DSG3-CAART cells has been initiated.
  • The Company anticipates announcing 28-day safety data for the fourth dose cohort in the first quarter of 2022.
  • For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).

Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021

Retrieved on: 
Friday, October 15, 2021
Infection, Technology, Cabaletta, Autoantibody, Podocyte, Private Securities Litigation Reform Act, Plasma protein binding, Proteinuria, Kidney, Immunity, Risk, Security (finance), MN, Dialysis, Kidney failure, CAR, FDA, Disease, Health, MuSK protein, Clinical trial, Penn, Patient, Public health, U.S. Securities and Exchange Commission, Form 10-K, Company, University, Annual report, Nephrotic syndrome, University of Pennsylvania, Safety, Pemphigus, Research, Ablation, Pharmaceutical industry

PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that data from in vitro studies supporting the early preclinical validation of PLA2R-Chimeric AutoAntibody Receptor T (CAART) cell candidates will be presented at ASN Kidney Week 2021. The data will be presented as an oral abstract by Aimee Payne, M.D., Ph.D., Professor of Dermatology at the University of Pennsylvania’s Perelman School of Medicine and co-chair of the Scientific Advisory Board and co-founder at Cabaletta Bio at the American Society of Nephrology (ASN) Kidney Week 2021 being held virtually from November 4-7, 2021.

Key Points: 
  • PLA2R-CAART is one of seven CAAR T programs that have emerged from the Cabaletta Approach to selective B cell Ablation (CABA) platform.
  • The lead preclinical product candidate, MuSK-CAART, is designed as a potential treatment for patients with MuSK-associated myasthenia gravis, with an IND submission planned by the end of 2021.
  • Primary membranous nephropathy (MN) is a B cell-mediated autoimmune disease that affects the kidneys.
  • Approximately 70-80% of the 15,000 primary MN patients in the U.S. have autoantibodies directed to the phospholipase A2 receptor (PLA2R) on kidney podocytes.

Hologic to Acquire Bolder Surgical for $160 Million, Expanding its Surgical Franchise

Retrieved on: 
Thursday, October 14, 2021
Surgery, Medical Devices, Women, Consumer, Health, Science, Hospital, Organization, Mission statement, CO, Nasdaq, Dissection, Growth, EPS, Pediatrics, Polyp, SEC, Ablation, Efficiency, Health, News, Surgeon, GAAP, Fibroid, HOLX, Calendar, Review, Acquisition, Culture, Medical imaging, Management, Birth control, Security (finance), Risk management

Hologic estimates that there are five times more laparoscopic procedures in OB/GYN applications than in pediatrics, where Bolder focuses today.

Key Points: 
  • Hologic estimates that there are five times more laparoscopic procedures in OB/GYN applications than in pediatrics, where Bolder focuses today.
  • Becoming part of Hologic and its highly respected and well-known Surgical business is an exciting and pivotal junction for Bolder, said Robert Kline, Bolder Surgicals President and Chief Executive Officer.
  • Joining Hologic, with its similar mission, culture, and world-class portfolio of products, is an ideal fit for Bolder.
  • Bolder Surgical, CoolSeal, and JustRight are trademarks and/or registered trademarks of Bolder Surgical and/or its subsidiaries in the United States and/or other countries.

Hologic Expands its Omni® Hysteroscopy Offering in Europe

Retrieved on: 
Thursday, September 30, 2021
Surgery, Medical Devices, Women, Other Health, Radiology, Health, Consumer, General Health, Oncology, Omni, GYN, News, Sterilization, HOLX, Health, Smart contract, Science, Sale, Patient, Surgery, OR, Physician, Feedback, Hysteroscopy, Anesthesia, International, Awareness, Cervical stenosis, Ablation, EMEA, Uterus, Nasdaq, Internal bleeding, Birth control, Medical imaging, Computer data storage

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has launched its expanded Omni suite, a comprehensive gynecological surgical offering designed to optimize diagnostic and operative hysteroscopy, in Europe, Africa and the Middle East (EMEA).

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has launched its expanded Omni suite, a comprehensive gynecological surgical offering designed to optimize diagnostic and operative hysteroscopy, in Europe, Africa and the Middle East (EMEA).
  • The offering now includes a versatile Omni 30 hysteroscope, the Omni Lok cervical seal and the Omni 5 French seal, which complement the companys existing portfolio of GYN surgical solutions and extend physicians choices.
  • The addition of the Omni Lok cervical seal and the Omni 5 French seal cap to Hologics portfolio supports procedural efficiency.
  • Physician questionnaire after video introduction to device; N=15
    2 Hologic Data on file, VER-09159, bench test utilizing a uterine model; N=22
    3 Hologic data on file.

Cabaletta Bio to Present at the Chardan 5th Annual Genetic Medicines Conference

Retrieved on: 
Tuesday, September 28, 2021
Clinical trial, Pemphigus, Health, Conference, News, FDA, Patient, Webcast, Ablation, MuSK protein, GLOBE, Pharmaceutical industry

A live webcast of the fireside chat will be available on the News and Events section of the companys website at www.cabalettabio.com .

Key Points: 
  • A live webcast of the fireside chat will be available on the News and Events section of the companys website at www.cabalettabio.com .
  • Following the presentation, a replay of the webcast will be available on the website for 90 days.
  • For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).
  • The Companys lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.

Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel

Retrieved on: 
Tuesday, September 7, 2021

PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel.

Key Points: 
  • PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel.
  • Mr. Gerard most recently served as Associate General Counsel at Spark Therapeutics, a member of the Roche Group.
  • Mr. Gerard also worked as Assistant General Counsel at Aramark.
  • He began his legal career at K&L Gates LLP, later joining Morrison & Foerster LLP before assuming his roles as in-house counsel.

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Retrieved on: 
Thursday, September 2, 2021
Company, GLOBE, Health, Clinical trial, MuSK protein, Pemphigus, Ablation, Patient, Conference, FDA, News, Morgan Stanley, Pharmaceutical industry, Management

Members of management will also be available for one-on-one meetings.

Key Points: 
  • Members of management will also be available for one-on-one meetings.
  • H.C. Wainwright 23rd Annual Global Investment Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a pre-recorded fireside chat, which will become available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m.
  • Both presentations will be available on the News and Events section of the companys website at www.cabalettabio.com .
  • For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).

Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV

Retrieved on: 
Wednesday, August 18, 2021
MPV, CAR, Private Securities Litigation Reform Act, Annual report, Political movement, DLT, U.S. Securities and Exchange Commission, Protein, DSG1, Skin, GLOBE, Desmoglein-1, Disease, Health, Autoantibody, Cell, Clinical trial, MuSK protein, Infection, Pemphigus, Public health, Ablation, Safety, Risk, Patient, Immunity, DSG3, Â, FDA, Infrared spectroscopy correlation table, Security (finance), Form 10-K, Vaccine, Pharmaceutical industry

PHILADELPHIA, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced 28-day data from the second dose cohort, at the 100 million cell dose level, in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV).

Key Points: 
  • The DesCAARTes trial has initiated dosing of patients in the third cohort at a treatment dose of 500 million DSG3-CAART cells.
  • Absent DLTs in the third cohort, a fourth dose cohort using 2.5 billion cells is also anticipated to initiate dosing this year.
  • Cabaletta will continue to provide additional data on a cohort-by-cohort basis for the DesCAARTes trial as they become available.
  • For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).

Cabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 5, 2021
Company, Clinical trial, U.S. Securities and Exchange Commission, Investment, Morgan, MPV, Food and Drug Administration, Neurotoxicity, MuSK protein, Infrared spectroscopy correlation table, Coronavirus Scientific Advisory Board (Turkey), Private Securities Litigation Reform Act, Limited liability company, Ablation, Chimera, Conference, Program, Health, Patient, Growth, COVID-19, Annual report, Board, DLT, Audit committee, ATM, Real-time, Risk, Director, Form 10-K, Research, AbbVie, Safety, Bureau of Oceans and International Environmental and Scientific Affairs, Head, Cytokine release syndrome, Food, Security (finance), Pemphigus, GLOBE, Pharmaceutical industry

PHILADELPHIA, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported financial results for the second quarter ended June 30, 2021, and provided a business update.

Key Points: 
  • In May 2021, Cabaletta announced acute safety data from three patients in the first cohort in the DesCAARTes trial.
  • As of August 4, 2021, no dose limiting toxicities (DLTs) or clinically relevant adverse events, including cytokine release syndrome or neurotoxicity, were observed.
  • Cabaletta will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference in September 2021.
  • Cabaletta will present a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference in September 2021.

Adagio Medical Reports 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Presents Recent Developments of Pulsed Field Cryoablation Technology

Retrieved on: 
Tuesday, August 3, 2021
Interventional radiology, Medicine, Clinical medicine, Medical specialties, Cryoablation, Ablation, Cardiac electrophysiology, Surgical oncology

The study enrolled 79 patients of which 45 patients had persistent AF with average duration of more than three (3) years from first diagnosis.

Key Points: 
  • The study enrolled 79 patients of which 45 patients had persistent AF with average duration of more than three (3) years from first diagnosis.
  • At 12 months, freedom from AF after a single procedure was 82%, with 1.5% procedural complications rate when using newer generations of ULTC technology.
  • In persistent AF patients, freedom from AF was 85%.
  • We have recently announced the initiation of the study in patients with monomorphic VT and are actively pursuing pulsed field cryoablation (PFCA), which combines ULTC and pulsed field ablation (PFA) technologies."